Events

Australian UDI update and guest speakers on the value of UDI for procurement and inventory management in hospitals.

The TGA Good Manufacturing Practice Forum returned to Sydney on 21 March 2023.

This webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be conditionally classified as Schedule 8 (controlled drug) in the Poisons Standard.

This webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be classified as Schedule 8 (controlled drug) when prescribed by a psychiatrist.

In this webinar we will provide an update on the Australian UDI implementation and discuss the challenges and benefits of having UDI in healthcare and the role of hospitals and other healthcare providers in relation to using UDI.

This webinar will explain labelling requirements for finished MCP in detail.

This webinar will guide you through the process of charging for regulatory activities, the medicinal cannabis funding model and the fees and charges structure and amounts proposed to commence on 1 July 2023.

The final webinar in this series will explore the impact changes to the EU MDR will have on consent to supply and market notifications.

The final webinar in this series will explore the impact changes to the EU MDR will have on consent to supply and market notifications.

This webinar will focus on how the changes under the EU MDR will affect manufacturer evidence and variations to the ARTG.

Changes to the formatting and structure of the Poisons Standard will come into effect from 1 February 2023

Presentation on the new formatting and structure of the Poisons Standard

This is the second in a series of three educational webinars outlining what regulatory actions are required as a result of changes under the EU MDR, with a focus on manufacturer evidence and variations to the ARTG.

This webinar will outline what regulatory actions are required as a result of changes under the EU MDR, and how the TGA will streamline the transition.

This is the first in a series of three educational webinars outlining what regulatory actions are required as a result of changes under the EU MDR.

The purpose of this webinar was to help sponsors understand how to use the Listed Medicines Evidence Guidelines to compile a robust evidence package that supports the efficacy of their listed medicine.

Presentation at the RACI Pharmaceutical Science Group (NSW) Seminar/Webinar, information for manufacturers of medicinal products on Computerised Systems - establishing and maintaining data integrity

A webinar covering how to view and respond to notifications in the Consent for Non-compliance Dashboard

This webinar will cover the process of submitting evidence of compliance with the EPs for devices in a consent application in a live demonstration.

This webinar will guide you through the process of applying for consent to import, supply or export a medical device non-compliant with the Essential Principles.

Guest speakers from Zebra Technologies will share observations and learnings from the UK Scan4Safety pilot.

Guest speakers from Zebra Technologies will share observations and learnings from the UK Scan4Safety pilot.

This webinar provides information on the third UDI Consultation Paper and runs through the submission process. It also includes a project update and question-and-answer session.

Understand the key findings of the independent expert report on the risks of intentional self-poisoning with paracetamol and have your questions answered about the TGA’s consultation (starting mid-September) on the possible options for changing access or purchasing controls through the Poisons Standard.

A webinar on the key findings from the independent expert report on the risks of intentional self-poisoning with paracetamol and options for amending the Poisons Standard